Table 1.
Distribution of 272 patients with prostate cancer from the main and control groups according to separate prognosis factors.
| Criterion | Group |
Diff. reliability (p) | ||
|---|---|---|---|---|
| Main (protons + phot.) | Control (photons) | |||
| Mean age (years) | 66.9 ± 6.4 | 69.0 ± 5.8 | p > 0.05 | |
| Stage | T1N0M0 | 11.2 ± 4.1% | 16.6 ± 4.7% | >0.05 |
| T2N0M0 | 41.1 ± 3.9% | 39.3 ± 3.6% | >0.05 | |
| T3-4N0M0 | 47.6 ± 3.6% | 44.0 ± 3.4% | >0.05 | |
| T2-3N1M0 | 6.1 ± 1.8% | 5.1 ± 1.7% | >0.05 | |
| PSA | Mean init. (ng/ml) | 28.7 ± 3.5 | 28.0 ± 2.7 | >0.05 |
| pts with PSA > 50 ng/ml | 15.8 ± 4.4% | 11.4 ± 2.9% | >0.05 | |
| Gleason index (mean) | 6.33 ± 0.12 | 6.31 ± 0.1 | p > 0.05 | |
| Progress risk group | Lowa | 7.0 ± 3.1% | 3.8 ± 1.2% | >0.05 |
| Intermediateb | 36.0 ± 4.0% | 46.5 ± 6.6% | >0.05 | |
| Highc | 57.0 ± 5.2% | 49.7 ± 5.0% | >0.05 | |
| Neoadjuvant HT | Carried out | 95.4% | 94.9% | >0.05 |
| Mean time (mon) | 6.39 ± 1.0 | 6.37 ± 0.66 | >0.05 | |
| Mean irradiation doses | Prostate | 71.8 ± 0.1 Gy(RBE) | 68.6 ± 0.4 Gy | <0.01 |
| Small pelvis | 44.9 ± 0.4 Gy(RBE) | 44.8 ± 0.3 Gy | >0.05 | |
| Without whole small pelvis irradiation | 14.0 ± 4.2% | 13.9 ± 3.0% | >0.05 | |
| Previous surgeries at urinary tracts | TUR | 14.3 ± 4.1% | 16.6 ± 4.7% | >0.05 |
| Adenomectomy | 6.3 ± 3.3% | 8.9 ± 2.8% | >0.05 | |
| Cystostomy | 2.7 ± 2.3% | 5.2 ± 1.7% | >0.05 | |
| Observation median (months) | Group (at whole) | 67.8 ± 3.1 | 71.6 ± 2.9 | >0.05 |
| Boost: 3.0 Gy(RBE) × 8 fr | 97.9 ± 2.1 | |||
| Boost: 4.0 Gy(RBE) × 5 fr | 56.4 ± 2.3 | |||
| Boost: 5.5 Gy(RBE) × 3 fr | 25.4 ± 1.8 | |||
a
T1-2N0, G < 6, PSA ≤ 10.
b
T3N0, or G-6–7, or PSA-10–20.
c
T4N0, T1-4N1, or G > 7, or PSA > 20.